Safety and Effectiveness of Intramuscular Methylprednisolone for Treating Hand Osteoarthritis in Patients Aged 16 and Older

What this Trial Is About

Researchers are evaluating the efficacy and safety of intramuscular methylprednisolone in patients with hand osteoarthritis. The main focus is to compare the effect on hand pain four weeks after a single injection of 120mg methylprednisolone, 40mg methylprednisolone, or placebo during the first 16 weeks, which is the randomized controlled trial phase of the study. Participants receive one intramuscular injection of either 120mg methylprednisolone, 40mg methylprednisolone, or placebo at the start of the trial. After this, in an open-label phase from week 16 to week 48, all participants may receive 120mg methylprednisolone injections on demand if they have hand pain over 30mm on a 0-100mm visual scale and at least 16 weeks have passed since their last injection. During this phase, a maximum of two injections may be given. Throughout the study, participants will visit the hospital for injections, ultrasound assessments, joint and grip strength examinations, blood tests, and hand X-rays. Hand pain and function will be regularly measured using various scales and questionnaires up to week 48. Safety and side effects of the treatments will also be monitored closely during the entire study period.

The Efficacy and Safety of Intramuscular Methylprednisolone in Patients With Hand OsteoArthritis